Novel 2,7-Substituted (<i>S</i>)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor γ Partial Agonists with Protein–Tyrosine Phosphatase 1B Inhibition-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel 2,7-Substituted (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor γ Partial Agonists with Protein–Tyrosine Phosphatase 1B Inhibition

Published:2015 Issue:12 Volume:63 Page:998-1014
ISSN:0009-2363
Container-title:Chemical and Pharmaceutical Bulletin
language:en
Short-container-title:CHEMICAL & PHARMACEUTICAL BULLETIN

Author:

Otake Kazuya¹,Azukizawa Satoru¹,Takeda Shigemitsu¹,Fukui Masaki¹,Kawahara Arisa¹,Kitao Tatsuya¹,Shirahase Hiroaki¹

Affiliation:

1. Drug Discovery Research Department, Kyoto Pharmaceutical Industries, Ltd.

Publisher

Pharmaceutical Society of Japan

Subject

Drug Discovery,General Chemistry,General Medicine

Link

https://www.jstage.jst.go.jp/article/cpb/63/12/63_c15-00508/_pdf

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tetrazoles and Related Heterocycles as Promising Synthetic Antidiabetic Agents;International Journal of Molecular Sciences;2023-12-06

2. Design of a multi-target focused library for antidiabetic targets using a comprehensive set of chemical transformation rules;Frontiers in Pharmacology;2023-11-02

3. Boron Trifluoride‐Mediated Synthesis of Oxazole N ‐oxides;ChemistrySelect;2022-12-20

4. Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents;ChemMedChem;2022-10-26

5. Recent updates on development of protein-tyrosine phosphatase 1B inhibitors for treatment of diabetes, obesity and related disorders;Bioorganic Chemistry;2022-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP